Taris Biomedical, a drug-delivery company based in Lexington, Mass., that focuses on therapies for genitourinary diseases, has raised $18.3 million in Series B financing, according to Fierce Drug Delivery.  Investors were Third Rock Ventures, Flagship Ventures, Flybridge Capital Partners and Polaris Venture Partners.

"This investment will allow us to advance our lead product candidate, Lidocaine Releasing Intravesical System (LiRIS), into later stage clinical development for the treatment of multiple bladder disorders, and to continue to build the rest of our pipeline of novel therapeutics, leveraging common, minimally invasive urological procedures," CEO Sarma Duddu said in a statement.

Taris is developing a platform of semi-permeable tubes that can be inserted into patients for therapy.